Ajuju Ajuju Banyere Sunitinib Malate 丨 AASraw
AASraw na-emepụta Cannabidiol (CBD) ntụ ntụ na Hemp Ezigbo Mmanụ na nnukwu!

Sunitinib Malate

 

  1. Sunitinib Malate Nyocha
  2. Kedu ihe anyị nwere ike iji Sunitinib Malate mee?
  3. Kedu ka Sunitinib Malate si arụ ọrụ?
  4. Kedu ka esi ewere Sunitinib Malate?
  5. Kedu ka esi echekwa Sunitinib Malate?
  6. Kedu otu anyị siri mara mmetụta nke Sunitinib Malate?
  7. Kedu ọgwụ ndị ọzọ ga-emetụta Sunitinib Malate?
  8. FDA kwadoro Sunitinib Malate Dị ka Ọgwụgwọ Adjuvant Nke Renal Cell Carcinoma
  9. Ebee ka m nwere ike zụta Sunitinib Malate Online?

 

Sunitinib Malate (CAS:341031-54-7) achọpụtara na SUGEN, ụlọ ọrụ biotechnology nke butere ndị na-egbochi protein kinase. Ọ bụ nke atọ na usoro nke ogige gụnyere SU5416 na SU6668. Ebumnuche ahụ bụ nke ATP mimic nke ga-asọ mpi na ATP maka njikọta na saịtị nke catalyine receptor tyrosine kinases. Echiche a mere ka e mepụta ọtụtụ obere molecule tyrosine kinase inhibitors, gụnyere Gleevec, Sutent, Tarceva na ọtụtụ ndị ọzọ.

 

Sunitinib Malate Nyocha

Sunitinib Malate bụ odo odo na ntụ ntụ. Sunitinib Malate bụ obere-molekul multi-ezubere iche ihe nnabata tyrosine kinase (RTK) mmechi. Na Jenụwarị 26, 2006, US FDA kwadoro ka onye ọrụ ahụ gosipụtara maka ịgwọ carcinoma akwara renal (RCC) na etuto na-eguzogide ọgwụ eriri afọ (GIST). Maka ebumnuche ndị a, Sunitinib Malate dịkarịsiri ka usoro eji arụ ọrụ ọnụ. Sunitinib Malate na-egbochi akara ngosi cellular site na iche ọtụtụ RTKs. Ndị a na-agụnye ndị na-anabata ihe na-akpata platelet (PDGF-R) na ndị na-anabata ihe uto nke endothelial (VEGF-R). Sunitinib Malate na-egbochi KIT (CD117), RTK nke na-eme ka ọtụtụ GIST. Na mgbakwunye, Sunitinib Malate na-egbochi RTK ndị ọzọ gụnyere RET, CSF-1R, na flt3.

 

Kedu ihe anyị nwere ike iji Sunitinib Malate mee? 

A na-eji Sunitinib Malate gwọọ ndị toro eto nwere ọrịa akụrụ na-agbasaghị (ebe a) na ndị nọ n'ihe ize ndụ nke RCC ịlaghachi ọzọ mgbe a wachara ha ahụ.

A na-eji Sunitinib Malate agwọ nnukwu ọrịa akụrụ (akụrụngwa akụrụngwa akụrụngwa ma ọ bụ RCC).

A na-eji Sunitinib Malate agwọ ọrịa kansa nke obere afọ, eriri afọ, ma ọ bụ esophagus a na-akpọ eriri afọ stromal tumor (GIST) na mgbe ị takenụrụla ọgwụ imatinib mesylate na ọ kwụsịghị ọrịa kansa anaghị eto eto ma ọ bụ na ịnweghị ike ịnara imatinib mesylate. Gleevec bụ ụghalaahia edenyere nke Novartis Pharmaceuticals Corporation.

A na-eji Sunitinib Malate agwọ ụdị ọrịa kansa pancreatic a maara dị ka etuto pancreatic neuroendocrine (pNET) nke nwere ọganihu na enweghị ike ịgwọ ya na ịwa ahụ.

 

Kedu ka Sunitinib Malate si arụ ọrụ?

Sunitinib Malate bụ onye na-egbochi obere mkpụrụ ndụ nke ọtụtụ ihe na-enweta tyrosine kinases, ụfọdụ n'ime ha na-ebute uto tumo, pathologic angiogenesis, na metastatic progress of cancer. Onye ọrụ ahụ na-egbochi ndị nabatara ihe na-akpata platelet - (PDGFRα na PDGFRβ), ndị na-anabata ihe na-akpata uto nke uto (VEGFR1, VEGFR2, na VEGFR3), sel cell na-anabata ihe (KIT), FMS dị ka tyrosine kinase 3, ihe na-akpali akpali na-akpali akpali. pịnye 1, na mkpụrụ ndụ glial sel nke nweta ihe na-akpata ihe nnata neurotrophic (RET). E gosiputara Sunitinib Malate igbochi ọrụ na ọrụ nke ndị na-anabata tyrosine kinases na nnwale biochemical na cellular na nnwale mkpụrụ ndụ cell. Isi metabolite nke Sunitinib Malate na-egosiputa ike dika ihe ndi nne na nna na nyocha nke biochemical na cellular.

Sunitinib Malate na-egbochi phosphorylation nke ọtụtụ ihe nnabata tyrosine kinases (PDGFRβ, VEGFR2, KIT) na tumo xenografts na-ekwupụta nnabata tyrosine kinase na vivo ma gbochie uto tumo na metastasis na ụdị nnwale ụfọdụ. Onye ọrụ ahụ na-egbochi uto nke mkpụrụ ndụ tumo na-ekwupụta dysregulated target receptor tyrosine kinases (PDGFR, RET, or KIT) in vitro and PDGFRβ-and VEGFR2-dependent tumor angiogenesis in vivo.

 

Sunitinib Malate

 

Kedu ka esi ewere Sunitinib Malate?

Ọgwụ dọkịta gị na-enye Sunitinib Malate ga-adabere n'ọtụtụ ihe. Ndị a gụnyere:

❶ ụdị na ogo ọnọdụ ị na-eji Sunitinib Malate na-emeso

Conditions ọnọdụ ahụike ndị ọzọ ị nwere ike ịnwe

Ọgwụ ndị ọzọ ị na-a takingụ

Dọkịta gị ga-emecha kwuo iwu nke pere mpe nke na-enye mmetụta achọrọ.

Ozi ndị a na-akọwa usoro eji eme ihe ma ọ bụ kwadoro. Otú ọ dị, jide n'aka na ị ga-ewere usoro ọgwụgwọ dọkịta gị nyere gị iwu. Dọkịta gị ga-ekpebi usoro ọgwụgwọ kachasị mma iji kwado mkpa gị.

 

♦ ♦dị ọgwụ ọjọọ na ike ya

Sunitinib Malate na-abia dika capsule i gha elo. Ọ dị na ike ndị a: 12.5 milligrams (mg), 25 mg, 37.5 mg, na 50 mg.

 

Ọgwụ maka ọrịa cancer nke eriri afọ

Dosdị usoro ọgwụgwọ Sunitinib Malate nke mbu nke ụbụrụ stromal (GISTs) bụ 50 mg otu ugboro kwa ụbọchị maka izu 4. Nke a na-esote izu 2 na-enweghị ọgwụ. Mgbe ahụ, ị ​​ga-emeghachi usoro ahụ.

O yikarịrị ka ị ga-anọgide na-ewere Sunitinib Malate ruo mgbe ọrịa kansa gị ka njọ ma ọ bụ ahụ gị enweghị ike ịnagide ọgwụgwọ na ọgwụ ahụ. Dọkịta gị ga-ekpebi mgbe ị kwesịrị ịkwụsị ịitinụ Sunitinib Malate. Maka nkọwa banyere otu esi eji Sunitinib Malate emeso GIST, lee njikọ dị n'okpuru.

 

Dosage maka akụrụ akụrụ

A na-ejikwa Sunitinib Malate na-agwọ ụdị ọrịa akụrụ akụrụ akpọ carcinoma akụrụngwa akụrụ (RCC). Dosdị usoro ọgwụgwọ Sunitinib Malate maka RCC dị elu bụ 50 mg otu ugboro kwa ụbọchị maka izu 4. Nke a na-esote izu 2 na-enweghị ọgwụ. Mgbe ahụ, ị ​​ga-emeghachi usoro ahụ.

O yikarịrị ka ị ga-anọgide na-ewere Sunitinib Malate ruo mgbe ọrịa kansa gị ka njọ ma ọ bụ ahụ gị enweghị ike ịnagide ọgwụgwọ na ọgwụ ahụ. Dọkịta gị ga-ekpebi mgbe ị kwesịrị ịkwụsị ịitinụ Sunitinib Malate. Maka ama ndi ozo banyere otu esi eji Sunitinib Malate emeso RCC di elu, lee njikọ di n'okpuru.

 

Ọgwụ onunu ogwu maka ọgwụ adjuvant nke akụrụ akụrụ

A na-ejikwa Sunitinib Malate dịka ọgwụ adjuvant maka ụdị ọrịa akụrụ akụrụ na-akpọ RCC mgbe nephrectomy (mwepụ nke akụrụ). Na mbụ onunu ogwu nke Sunitinib Malate maka ojiji a bụ 50 mg otu ugboro kwa ụbọchị maka izu 4. Nke a na-esote izu 2 na-enweghị ọgwụ. You'll ga-emeghachi usoro a ruo oge itoolu. Maka nkọwa banyere otu esi eji Sunitinib Malate eme ihe dị ka ọgwụgwọ adjuvant maka RCC, lee njikọ dị n'okpuru.

 

Ngwọta ọrịa cancer

Agedị usoro ọgwụgwọ Sunitinib Malate maka tumor neuroendocrine (pNETs) dị elu bụ 37.5 mg otu ugboro kwa ụbọchị.

O yikarịrị ka ị ga-anọgide na-ewere Sunitinib Malate ruo mgbe ọrịa kansa gị ka njọ ma ọ bụ ahụ gị enweghị ike ịnagide ọgwụgwọ na ọgwụ ahụ. Dọkịta gị ga-ekpebi mgbe ị kwesịrị ịkwụsị ịitinụ Sunitinib Malate.

 

Amara: onunu ogwu bu ntughari aka, biko nyere aka lelee nkọwa ndi ozo site na weebụsaịtị a:www.fda.gov .

 

 

Kedu ka esi echekwa Sunitinib Malate?

Debe ọgwụ a n'ime akpa ya wee bata, mechie emechi, ma ghara iru ụmụaka. Na-echekwa ya na ime ụlọ okpomọkụ ma pụọ ​​na okpomọkụ na mmiri (ọ bụghị n'ime ime ụlọ ịwụ).

Ọ dị mkpa ka ị ghara ịchọta ọgwụ niile ma hụ ụmụaka dị ka ọtụtụ nchịkọta (dịka ntụrụndụ kwa izu na ndị na-ahụ anya, creams, patches, and inhalers) abụghị ụmụaka na-eguzogide ma ụmụaka nwere ike imeghe ha ngwa ngwa. Iji kpuchido ụmụntakịrị site na nsị, mechie mkpọchi nchebe ozugbo tinye ọgwụ ahụ na ebe nchekwa - nke dị elu ma pụọ ​​ma n'anya ha.

Ekwesịrị itinye ọgwụ ndị na-achọghị usoro n'ụzọ pụrụ iche iji hụ na anụ ụlọ, ụmụaka, na ndị ọzọ enweghị ike iri ha. Agbanyeghị, ịkwesighi iwepụ ọgwụ a n'ụlọ mposi. Kama nke ahụ, ụzọ kachasị mma iji tufuo ọgwụ gị bụ site na mmemme nloghachi ọgwụ. Gwa onye dibia ogwu gi ma obu kpoturu ndi nkpuru ahihia / ebe ana akpo ahihia ka imuta ihe omumu na obodo gi. Hụ Mkpofu Ahụhụ nke FDA Ọgwụ weebụsaịtị maka ozi ndị ọzọ ma ọ bụrụ na ịnweghị ohere ịnweta usoro mmeghachị.

 

Kedu otu anyị siri mara mmetụta nke Sunitinib Malate?

A na-ahụta ihe ọjọọ dị iche iche nke Sunitinib Malate dị ka ihe jikwaa jikwaa ya na nsogbu nke ihe ọghọm dị obere.

Ihe ojoo ojoo ndi ozo na Sunitinib Malate bu ndi ike gwuru, oria ohia, ọgbụgbọ, anorexia, ọbara mgbali elu, acha odo odo, mmeghari akpukpo ukwu, na stomatitis. mgbe mgbe na Sunitinib Malate karịa placebo gụnyere afọ ọsịsa, anorexia, ụcha akpụkpọ, mucositis / stomatitis, asthenia, uto gbanwere, na afọ ntachi. Achọrọ mbelata ọgwụ na 50% nke ndị ọrịa mụọ na RCC iji jikwaa nsị dị mkpa nke onye ọrụ a.

Ihe siri ike (ọkwa 3 ma ọ bụ 4) ihe omume na-eme na -10% nke ndị ọrịa ma gụnye ọbara mgbali elu, ike ọgwụgwụ, asthenia, afọ ọsịsa, na ọgwụ chemotherapy-ebute acry erythema. Ọdịiche ụlọ nyocha metụtara ọgwụgwọ Sunitinib Malate gụnyere lipase, amylase, neutrophils, lymphocytes, na platelet. Hypothyroidism na erythrocytosis na-agbanwe agbanwe ejikọtara ya na Sunitinib Malate. Enwere ike ijikwa ọtụtụ ihe omume ọjọọ site na nlekọta nkwado, nkwụsịtụ ọgwụ, ma ọ bụ mbelata ọgwụ.

Nnyocha e mere n'oge na-adịbeghị anya na MD Anderson Cancer Center tụnyere nsonaazụ nke ọrịa ndị na-arịa ọrịa cancer akwara natara Sunitinib Malate na usoro nhazi (50 mg / 4 izu na izu 2) na ndị natara Sunitinib Malate na ezumike ọgwụ ndị ọzọ na obere oge. (usoro ihe omume). A hụrụ na nlanarị zuru oke, nlanarị n'efu na nnabata ọgwụ dị elu karịa ndị ọrịa natara Sunitinib Malate na usoro ọzọ. Ndị ọrịa nwekwara ndidi ka mma na nsogbu dị njọ nke na-edugakarị na njedebe nke ọgwụgwọ nke ndị ọrịa kansa na-arịa ọrịa akwara.

 

Sunitinib Malate

 

Kedu ọgwụ ndị ọzọ ga-emetụta Sunitinib Malate?

Sunitinib Malate nwere ike ibute nnukwu nsogbu obi. Ihe ize ndụ gị nwere ike ịdị elu karịa ma ọ bụrụ na ị na-ejikwa ọgwụ ndị ọzọ maka ọrịa, ụkwara ume ọkụ, nsogbu obi, ọbara mgbali elu, ịda mba, ọrịa ọgụgụ isi, kansa, ịba, ma ọ bụ nje HIV.

Mgbe ụfọdụ ọ naghị adị mma iji ọgwụ ụfọdụ n'otu oge. Drugsfọdụ ọgwụ nwere ike imetụta ogo ọbara gị nke ọgwụ ndị ọzọ ị na-a ,ụ, nke nwere ike ịbawanye nsonaazụ ma ọ bụ mee ka ọgwụ ndị ahụ ghara ịdị irè. Gwa dọkịta gị gbasara ọgwụ gị niile, ọkachasị: ọgwụ osteoporosis.

Ndepụta a ezughi ezu. Ọgwụ ndị ọzọ nwere ike ịmetụta Sunitinib Malate, gụnyere ọgwụ ọgwụ na ọgwụ mgbochi, vitamin, na ngwaahịa ahịhịa. E depụtaghị mmekọrịta mmekọrịta ọgwụ niile enwere ike ịbụ ebe a.

 

FDA kwadoro Sunitinib Malate Dị ka Ọgwụgwọ Adjuvant Nke Renal Cell Carcinoma

Na November 16, 2017, Nchịkwa nri na ọgwụ ọjọọ kwadoro Sunitinib Malate (Sunitinib Malate, Pfizer Inc.) maka ọgwụgwọ adjuvant nke ndị okenye toro eto na-enwe nnukwu ihe egwu nke ịrịa carcinoma akụrụ na-esochi nephrectomy.

Nkwado dabeere na ọtụtụ etiti, mba ụwa, isi abụọ, ebe a na-achịkwa ebebo, ikpe (S-TRAC), na ndị ọrịa 615 nwere nnukwu ihe ọghọm nke RCC na-abịaghachi mgbe ọ na-eso nephrectomy. Ejiri 1: 1 mechie ndị ọrịa iji nweta 50 mg Sunitinib Malate otu ugboro kwa ụbọchị, izu 4 na ọgwụgwọ na-esote izu 2, ma ọ bụ placebo. Ọrịa Median na-enweghị ọrịa maka ndị ọrịa na-ewere Sunitinib Malate bụ afọ 6.8 (95% CI: 5.8, eruteghị) ma e jiri ya tụnyere afọ 5.6 (95% CI: 3.8, 6.6) maka ndị ọrịa na-enweta placebo (HR = 0.76; 95% CI: 0.59) , 0.98; p = 0.03). N'oge nyocha DFS, data nlanarị zuru oke etobeghị.

Mmeghachi omume na-adịghị mma (≥25%) na Sunitinib Malate bụ ike ọgwụgwụ / asthenia, afọ ọsịsa, mucositis / stomatitis, ọgbụgbọ, mbelata nri / nri nri, agbọ agbọ, mgbu mgbu, ọrịa aka ụkwụ, ọbara mgbali elu, ọbara ọgbụgba, dysgeusia / uto gbanwere , dyspepsia na thrombocytopenia. Nkọwa aha ahụ nwere ịdọ aka ná ntị gbara ọkpụrụkpụ iji mee ka ndị ọkachamara ahụike na ndị ọrịa mara banyere ihe egwu nke hepatoxicity, nke nwere ike ibute ọdịda imeju ma ọ bụ ọnwụ.

Ntuziaka nke Sunitinib Malate maka ọgwụ adjuvant nke RCC bụ 50 mg okwu ọnụ otu ugboro kwa ụbọchị, yana ma ọ bụ na-enweghị nri, izu 4 na ọgwụgwọ na-esote izu 2 maka izu itoolu na izu isii.

 

Kwuru: Ozi ederede zuru ezu dị na:accessdata.fda.gov  PDF 

 

Ebee ka m nwere ike zụta Sunitinib Malate Online? 

E nwere ọtụtụ soplaya / ndị na-emepụta Sunitinib Malate ntụ ntụ n'ahịa, ịchọta ezigbo nke dị ezigbo mkpa maka ndị niile chọrọ ngwaahịa a ngwa ngwa. Mgbe anyị kpebiri ịzụta Sunitinib Malate ntụ ntụ n'ahịa, ọ dị anyị mkpa ịmụtakwu ihe banyere ya, mara otu esi eji ya ma ọ bụ usoro ọrụ, ihe egwu ọ bụla mgbe anyị were Sunitinib Malate powder…. Na mgbakwunye, ọnụahịa na ogo ga-abụrịrị nchegbu anyị tupu ịzụta ya.

Mgbe anyị nyochachara datas site na ahịa, ma e jiri ya tụnyere ọtụtụ ndị na-eweta ngwaahịa, AASraw dị mma maka ndị chọrọ ịzụta ọtụtụ Sunitinib Malate ntụ ntụ, A na-achịkwa mmepụta ha n'ụzọ doro anya n'okpuru ọnọdụ cGMP, a ga-enyocha àgwà ahụ n'oge ọ bụla ma ha nwere ike ịnye akụkọ nyocha niile mgbe ị na-enye ya iwu. Banyere Sunitinib Malate ntụ ntụ na-efu / ọnụahịa, ọ kwesịrị ịbụ ihe ezi uche dị na ya, n'anya m. N'ihi na enwetara m ọtụtụ ọnụ ahịa sitere na ndị na-eweta ngwa ahịa Sunitinib Malate dị iche iche, ma e jiri ya tụnyere ogo, echere m na aasraw agaghị abụ nhọrọ ọjọọ.

 

Reference

[1] Nchịkwa nri na ọgwụ ọjọọ. Sunitinib (Sutent) Na-edepụta ozi. 2015.

[2] CA Naranjo, U. Busto, na EM Ndị na-ere ahịa, "Usoro maka ịkọwa ihe gbasara nke puru omume nke mmeghachi omume ọgwụ ọjọọ," Clinical Pharmacology and Therapeutics, vol. 30, mba. 2, peeji nke 239-245, 1981.

[3] Z. Ansari na MK George, "ogwu na-ebute ogwu thrombocytopenia nke abuo na sunitinib na onye nwere oria akwara akwara metastatic: akuko ikpe," Journal of Medical Case Reports, vol. 7, edemede 54, 2013.

[4] K. Sakai, K. Komai, D. Yanase, na M. Yamada, "Plasma VEGF dị ka ihe nrịba ama maka nyocha na ọgwụgwọ nke neuropathy vasculitic," Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, mba. 2, ederede 296, 2005.

[5] Mediclọ Ọrụ Ọgwụ Europe. Sunitinib (AHUT). Nchịkọta nke njirimara ngwaahịa. 2015.

[6] Pajares B, Torres E, Trigo JM et al. Ndị na-emechi Tyrosine kinase na mmekọrịta ọgwụ: nyocha na ndụmọdụ bara uru. Ọrịa Clinic Transl Oncol 2012; 14: 94-101.

[7] Teo YL, Ho HK, Chan A. Mmekọrịta ọgwụ-ọgwụ ọgwụ metabolism metụtara ọgwụ ọgwụ na tyrosine kinase inhibitors: nghọta dị ugbu a, nsogbu na ndụmọdụ. Br J Clin Pharmacol 2015; 79: 241-253.

[8] Jamie Dlugosch (2009-03-13). "Ndi biologics na Sutent chekwaa Pfizer?". Ntinye ego

[9] BMJ 31-Jan-2009 "NICE na ihe ịma aka nke ọgwụ cancer" p271

[10] Blay JY, Reichardt P (June 2009). "Ọrịa ụbụrụ stromal nke dị elu na Europe: nyocha nke emelitere ọgwụgwọ akwadoro". Ọkachamara Rev Anticancer Ther. 9 (6): 831–8. ma ọ bụ: 10.1586 / era.09.34. PMID 19496720. S2CID 23601578.

0 amasị
9014 Echiche

Ị nwere ike na-amasị

Comments na-emechi.